Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Selinexor

Review the clinical trials studying selinexor on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-19 of 19

A Study of the Drug Selinexor with Radiation Therapy in Patients with Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Status: Active
Location: 107 locations
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) with the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
Status: Active
Location: 27 locations
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Status: Active
Location: 19 locations
Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis
Status: Active
Location: 14 locations
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Status: Active
Location: 14 locations
Selinexor for the Treatment of Recurrent or Refractory Wilms Tumor and Other Pediatric Solid Tumors
Status: Active
Location: 13 locations
Testing Atezolizumab with Selinexor in People ≥ 12 Years Old with Alveolar Soft Part Sarcoma, The AXIOM Trial
Status: Active
Location: 12 locations
A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Status: Active
Location: 4 locations
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Status: Active
Location: 7 locations
Selinexor, Venetoclax, and Dexamethasone for the Treatment of t(11;14)-Positive Relapsed or Refractory Multiple Myeloma, SELVEDge Trial
Status: Active
Location: 3 locations
Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor for the Treatment of Non-rhabdomyosarcoma Soft Tissue Sarcoma
Status: Active
Location: 3 locations
Cytarabine and Daunorubicin Hydrochloride with or without Selinexor in Treating Older Patients with Acute Myeloid Leukemia
Status: Active
Location: 2 locations
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Low-Dose Selinexor and Choline Salicylate for the Treatment of Patients with Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Active
Location: See ClinicalTrials.gov
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors that have Returned after Previous Treatment
Status: Temporarily Closed to Accrual
Location: 34 locations
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Temporarily Closed to Accrual
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Selinexor in Combination with Carfilzomib, Daratumumab or Pomalidomide, and Dexamethasone for the Treatment of Patients with Multiple Myeloma Relapsing on Current Therapy
Status: Temporarily Closed to Accrual
Location: 2 locations
Implantable Microdevice for the Delivery of Drugs and their Effect on Tumors in Patients with Sarcoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas